Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer
Pre-analytical Phase Challenges and Biomarker Testing in HER2+ Metastatic Breast Cancer Key clinical takeaways: Metastatic breast cancer (mBC) is a complex, heterogeneous disease requiring multi...
12 Maalis 23min
Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification
Understanding HER2-low and HER2-ultralow classification in mBC In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binar...
17 Joulu 202525min
Understanding EP-NEC: Through Diagnosis, Treatment, and Support
In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressi...
7 Marras 202527min
Exploring the role of targeted radiopharmaceutical treatment in NETs
How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing,...
30 Syys 202521min
Tackling mPDAC: chemotherapy strategies that matter
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall surv...
19 Touko 202521min
Understanding Rare NSCLC Mutations: Insights, access and support
Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE)...
14 Touko 202520min
The HER2 diagnostic and treatment landscape in NSCLC
Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology B...
28 Huhti 202518min
The HER2 Diagnostic and Treatment Landscape in NSCLC
Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC,...
15 Huhti 202521min
